These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 20530795)

  • 1. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
    Goodyear O; Agathanggelou A; Novitzky-Basso I; Siddique S; McSkeane T; Ryan G; Vyas P; Cavenagh J; Stankovic T; Moss P; Craddock C
    Blood; 2010 Sep; 116(11):1908-18. PubMed ID: 20530795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
    Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
    Bao L; Dunham K; Lucas K
    Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
    Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
    Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
    Moreno-Bost A; Szmania S; Stone K; Garg T; Hoerring A; Szymonifka J; Shaughnessy J; Barlogie B; Prentice HG; van Rhee F
    Cytotherapy; 2011 May; 13(5):618-28. PubMed ID: 21171821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
    Gore SD; Baylin S; Sugar E; Carraway H; Miller CB; Carducci M; Grever M; Galm O; Dauses T; Karp JE; Rudek MA; Zhao M; Smith BD; Manning J; Jiemjit A; Dover G; Mays A; Zwiebel J; Murgo A; Weng LJ; Herman JG
    Cancer Res; 2006 Jun; 66(12):6361-9. PubMed ID: 16778214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
    Gaymes TJ; Shall S; MacPherson LJ; Twine NA; Lea NC; Farzaneh F; Mufti GJ
    Haematologica; 2009 May; 94(5):638-46. PubMed ID: 19407318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
    Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
    PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
    Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
    Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
    Wu Y; Sang M; Liu F; Zhang J; Li W; Li Z; Gu L; Zheng Y; Li J; Shan B
    Carcinogenesis; 2020 Jul; 41(7):894-903. PubMed ID: 32529260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
    Leclercq S; Gueugnon F; Boutin B; Guillot F; Blanquart C; Rogel A; Padieu M; Pouliquen D; Fonteneau JF; Grégoire M
    Eur Respir J; 2011 Nov; 38(5):1105-16. PubMed ID: 21540307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
    Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
    Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.
    Li B; Zhu X; Sun L; Yuan L; Zhang J; Li H; Ye Z
    Oncotarget; 2014 Nov; 5(21):10791-802. PubMed ID: 25301731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
    Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
    Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
    Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
    Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
    Tibes R; Al-Kali A; Oliver GR; Delman DH; Hansen N; Bhagavatula K; Mohan J; Rakhshan F; Wood T; Foran JM; Mesa RA; Bogenberger JM
    J Hematol Oncol; 2015 Oct; 8():114. PubMed ID: 26483188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
    Follo MY; Finelli C; Mongiorgi S; Clissa C; Chiarini F; Ramazzotti G; Paolini S; Martinelli G; Martelli AM; Cocco L
    Leukemia; 2011 Feb; 25(2):271-80. PubMed ID: 21109771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.
    Wang LX; Mei ZY; Zhou JH; Yao YS; Li YH; Xu YH; Li JX; Gao XN; Zhou MH; Jiang MM; Gao L; Ding Y; Lu XC; Shi JL; Luo XF; Wang J; Wang LL; Qu C; Bai XF; Yu L
    PLoS One; 2013; 8(5):e62924. PubMed ID: 23671644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell].
    Meng YS; Ma XX; Meng XQ; Wei R; Liu W; Ai GW; Zhang YX
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3406-10. PubMed ID: 18476539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
    Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.